Our observations suggest that GM-CSF blockade modulates inflammatory responses differently to TNF or IL-6 blockade and may provide a greater understanding of how GM-CSFRα/GM-CSF inhibition is effective in RA; they may also help identify additional diseases where targeting this pathway may provide benefit. This evidence concerns the gene TNF and rheumatoid arthritis.